{"id":"NCT01824290","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)","officialTitle":"A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-05","primaryCompletion":"2019-03-18","completion":"2021-03-10","firstPosted":"2013-04-04","resultsPosted":"2020-03-23","lastUpdate":"2021-11-05"},"enrollment":35,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"Tadalafil","otherNames":["LY450190","Cialis","Adcirca","IC351"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"ERA as specific PAH treatment","otherNames":[]}],"arms":[{"label":"Tadalafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.","primaryOutcome":{"measure":"Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":36.6,"sd":20.776},{"arm":"Tadalafil","deltaMin":60.48,"sd":20.41}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":23},"locations":{"siteCount":43,"countries":["United States","Austria","Belgium","Brazil","France","Germany","Israel","Italy","Japan","Mexico","Netherlands","Poland","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/5ejOJO01mwK2euskWAUoeu"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Headache","Upper respiratory tract infection","Arthralgia","Epistaxis","Influenza"]}}